Eli Lilly and Company successfully secured the transfer of the domain mounjaro-tirzepatida.shop after proving the respondent used it to impersonate the brand and offer unauthorized medication. The panel ruled that the respondent had no legitimate interest and acted in bad faith.
Case Snapshot
| Case Number | D2026-3545 |
|---|---|
| Complainant | Eli Lilly and Company |
| Respondent | yan balayas |
| Disputed Domain | mounjaro-tirzepatida.shop |
| Threat Tactic | Fake Stores |
| Decision Date | 2026-09-18 |
| Panelist | Mariia Koval |
| Outcome | Transfer |
| Official Source | https://www.wipo.int/amc/en/domains/search/text.jsp?case=D2026-3545 |
Facing Unauthorized Domain Registrations or Brand Abuse?
Our domain dispute attorneys represent trademark owners and businesses worldwide before WIPO, Forum (NAF), and CAC. Explore our Domain Name Disputes and Enforcement & Takedowns services, or request a free case evaluation.
Request Case EvaluationBusiness Risk: Impersonation and Unauthorized Pharmaceutical Sales
The registration of ‘mounjaro-tirzepatida.shop’ by the respondent, yan balayas, represents a severe commercial and regulatory threat through the operation of a fraudulent online pharmacy. By utilizing the MOUNJARO trademark within the domain, the respondent actively misled consumers in Brazil, creating a false association that suggested the site was an authorized outlet for the complainant’s legitimate pharmaceutical products. The absence of any disclosure regarding the lack of an official relationship between the respondent and Eli Lilly and Company further exacerbated this deception, heightening the risk that unsuspecting patients would unknowingly purchase counterfeit or unregulated medications under the guise of the established brand.
Beyond simple trademark infringement, the respondent’s activities posed significant safety and legal liabilities for the brand. The website not only purported to sell MOUNJARO without valid prescription requirements but also offered ‘retatrutide,’ an investigative medication that has not yet secured regulatory approval. Such unauthorized distribution of illicit substances under the cloak of a trusted brand significantly erodes customer trust and invites intense regulatory scrutiny. The transition of the domain from an active, fraudulent sales portal to an inactive status illustrates the transient nature of these tactics, yet the initial period of operation inflicted clear reputational damage by associating the complainant’s intellectual property with the high-risk, illegal sale of unverified pharmaceutical compounds.
Legal Analysis: Confusing Similarity, Lack of Rights, and Bad Faith
The panel determined that the disputed domain name, ‘mounjaro-tirzepatida.shop’, is confusingly similar to the Complainant’s MOUNJARO trademark. Despite the inclusion of the generic term ‘tirzepatida’—the International Nonproprietary Name for the product’s active ingredient—the panel found this insufficient to avoid a finding of confusing similarity. For brand owners, this reinforces the principle that appending descriptive or generic medical terms to a core brand identifier does not insulate a domain from UDRP challenges when the overall impression remains tied to the complainant’s mark.
Regarding rights or legitimate interests, the panel affirmed that the Respondent failed to establish any connection to the Complainant. There was no evidence that the Respondent was commonly known by the domain name, nor was the site utilized for a bona fide offering of goods or services. By purporting to sell pharmaceutical products without the requisite medical oversight or prescription, the Respondent failed to qualify for any fair use or legitimate noncommercial defense, highlighting the inherent illegitimacy of sites that attempt to masquerade as authorized distributors of restricted medication.
The panel concluded that the Respondent’s registration and use of the domain constituted bad faith, largely based on the intent to mislead consumers. The website’s active solicitation of sales for MOUNJARO products, combined with the unauthorized promotion of unapproved investigative medications like ‘retatrutide’, provided clear evidence of an intentional attempt to attract internet users for commercial gain. By creating a false association with the Complainant, the Respondent engaged in a deceptive practice that undermines consumer safety and directly impinges upon the Complainant’s extensive global trademark rights.
Strategic Deployment of Evidence in Pharmaceutical Domain Disputes
Eli Lilly’s successful recovery of the disputed domain rested on its meticulous documentation of the respondent’s temporary website operations. Even though the domain was inactive by the time of the final decision, the complainant submitted critical evidence—Annex 13 to the Complaint—that captured the site’s active state during the filing period. By preserving evidence of the site offering prescription-only MOUNJARO and unapproved substances like ‘retatrutide’ to Brazilian consumers, the complainant effectively demonstrated the respondent’s intent to deceive, fulfilling the bad faith requirement despite the site’s subsequent transition to an inactive status.
The legal strategy relied on neutralizing the respondent’s attempt to use descriptive naming conventions as a shield. The panel correctly dismissed the inclusion of the generic term ‘tirzepatida’ as insufficient to avoid a finding of confusing similarity with the well-known MOUNJARO trademark. This result underscores the importance for brand owners in the pharmaceutical sector to consistently map their global portfolio—including the 143 registrations cited here—against domain monitoring systems. The decision reinforces that unauthorized commercial exploitation of a brand, specifically when combined with the distribution of unapproved medications, creates an indefensible position for a respondent under the UDRP framework.
Practical Recommendations
- Capture time-stamped screenshots of the website and all sub-pages immediately upon discovery, even if the site is later taken down, to preserve evidence of bad faith use.
- Monitor global domain registrations for your primary trademarks paired with active pharmaceutical ingredients (APIs) to identify impersonation attempts before they go live.
- Explicitly document the lack of a ‘bona fide’ relationship by highlighting that the site requires no prescription, which directly contradicts standard legitimate distribution practices for your brand.
- Include evidence of the sale or promotion of unapproved investigative medications on the site to strengthen the argument of bad faith and risk to public health, increasing the likelihood of a successful UDRP outcome.
- Standardize the collection of evidence for cross-border infringement by mapping the targeted region (e.g., Brazil) to your local trademark registrations to demonstrate clear territorial confusion.
Frequently Asked Questions (FAQ)
Why was the domain ‘mounjaro-tirzepatida.shop’ considered confusingly similar to Eli Lilly’s trademark?
The WIPO panel determined that incorporating the trademark ‘MOUNJARO’ into the disputed domain created a high risk of consumer confusion, and the addition of the descriptive term ‘tirzepatida’—the generic active ingredient—did not distinguish the domain from the complainant’s brand or reduce the potential for deception.
What evidence did the panel use to determine that the respondent lacked rights or legitimate interests?
The panel found that the respondent was not commonly known by the domain name, had no authorization or license to use the ‘MOUNJARO’ trademark, and was not making a bona fide offering of goods; instead, the site was used to facilitate the unauthorized sale of pharmaceuticals without prescription requirements.
How did the complainant successfully prove bad faith registration and use?
Evidence showed the respondent used the domain to impersonate Eli Lilly’s brand to attract traffic for commercial gain. Critically, the respondent offered both the complainant’s product without a prescription and an unapproved, investigative drug (‘retatrutide’), confirming an intentional effort to deceive consumers and capitalize on the brand’s reputation.
What was the practical tactical outcome for this UDRP case?
The panel ordered the transfer of ‘mounjaro-tirzepatida.shop’ to Eli Lilly and Company. This decision serves as a key precedent for pharmaceutical brands to use when documenting unauthorized online sales of prescription and investigative medications as evidence of bad faith.
Found a fake shop using your brand?
Similar to the Eli Lilly case, unauthorized pharmaceutical sites targeting your consumers pose severe brand and regulatory risks. We can help you assess your UDRP eligibility to disrupt illicit distribution channels and protect your trademark reputation.
This case note is for informational purposes only and is not legal advice.
